| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2014: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2013: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2012: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
|---|
| Outline of Final Research Achievements |
West Nile virus (WNV) is the human-infectious virus, which sometimes causes lethal encephalitis / meningitis, and vaccine and therapeutics for human use have not been developed yet. In this study, we focued on the envelope (E)protein, which can induce protective immunity. By immunizing mice with recombinant WNV E protein combined with γ - polyglutamic acid (γ-PGA) nano particles that is cytotoxic T lymphocyte (CTL) - inducible novel adjuvant, we confirmed that CTL as well as antibody specific for the epitopes on WNV E protein are efficiently induced. These results indicate that recombinant WNV E protein combined with γ-PGA nano particles have the potential for candidate of novel WNV vaccine. Furthermore, we have establihed human monoclonal antibodies, which possess neutralizing and protective activities agains WNV, from Japanese encephalitis virus (JEV) vaccine - immunized volunteers, using WNV E protein and ISAAC technology. They may be applicable for antibody-based therapeutics.
|
